Clinical trial
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
NCT01962415
Study timeline
Study start (actual)2014-02-04Date precision: day
Registry last updated2025-12-15
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Primary Immunodeficiency (PID)unresolved
Congenital Bone Marrow Failure Syndromesunresolved
Inherited Metabolic Disorders (IMD)unresolved
Hereditary Anemiasunresolved
Inflammatory Conditionsunresolved
Juvenile Rheumatoid Arthritis (JRA)unresolved
Interventions
HydroxyureaDRUG · verified · RxNorm: hydroxyurea
AlemtuzumabDRUG · verified · RxNorm: alemtuzumab
FludarabineDRUG · verified · RxNorm: fludarabine
MelphalanDRUG · verified · RxNorm: melphalan
ThiotepaDRUG · verified · RxNorm: thiotepa
Sponsors & collaborators
Paul Szabolcslead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01962415 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.